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CT coronary angiography in patients with suspected angina 
due to coronary heart disease (SCOT-HEART): an open-label, 
parallel-group, multicentre trial
The SCOT-HEART investigators*
Summary
Background The benefi t of CT coronary angiography (CTCA) in patients presenting with stable chest pain has not 
been systematically studied. We aimed to assess the eff ect of CTCA on the diagnosis, management, and outcome of 
patients referred to the cardiology clinic with suspected angina due to coronary heart disease.
Methods In this prospective open-label, parallel-group, multicentre trial, we recruited patients aged 18–75 years referred 
for the assessment of suspected angina due to coronary heart disease from 12 cardiology chest pain clinics across 
Scotland. We randomly assigned (1:1) participants to standard care plus CTCA or standard care alone. Randomisation 
was done with a web-based service to ensure allocation concealment. The primary endpoint was certainty of the diagnosis 
of angina secondary to coronary heart disease at 6 weeks. All analyses were intention to treat, and patients were analysed 
in the group they were allocated to, irrespective of compliance with scanning. This study is registered with 
ClinicalTrials.gov, number NCT01149590.
Findings Between Nov 18, 2010, and Sept 24, 2014, we randomly assigned 4146 (42%) of 9849 patients who had been 
referred for assessment of suspected angina due to coronary heart disease. 47% of participants had a baseline clinic 
diagnosis of coronary heart disease and 36% had angina due to coronary heart disease. At 6 weeks, CTCA reclassifi ed 
the diagnosis of coronary heart disease in 558 (27%) patients and the diagnosis of angina due to coronary heart 
disease in 481 (23%) patients (standard care 22 [1%] and 23 [1%]; p<0·0001). Although both the certainty (relative risk 
[RR] 2·56, 95% CI 2·33–2·79; p<0·0001) and frequency of coronary heart disease increased (1·09, 1·02–1·17; 
p=0·0172), the certainty increased (1·79, 1·62–1·96; p<0·0001) and frequency seemed to decrease (0·93, 0·85–1·02; 
p=0·1289) for the diagnosis of angina due to coronary heart disease. This changed planned investigations (15% vs 1%; 
p<0·0001) and treatments (23% vs 5%; p<0·0001) but did not aff ect 6-week symptom severity or subsequent 
admittances to hospital for chest pain. After 1·7 years, CTCA was associated with a 38% reduction in fatal and non-
fatal myocardial infarction (26 vs 42, HR 0·62, 95% CI 0·38–1·01; p=0·0527), but this was not signifi cant.
Interpretation In patients with suspected angina due to coronary heart disease, CTCA clarifi es the diagnosis, enables 
targeting of interventions, and might reduce the future risk of myocardial infarction.
Funding The Chief Scientist Offi  ce of the Scottish Government Health and Social Care Directorates funded the trial 
with supplementary awards from Edinburgh and Lothian’s Health Foundation Trust and the Heart Diseases 
Research Fund.
Copyright © Newby et al. Open Access article distributed under the terms of CC BY.
Introduction
Many patients with recent onset angina have a cardiac 
event within 1–2 years1 and will benefi t from intervention.2 
Although the rapid clinical assessment of patients with 
suspected angina due to coronary heart disease is 
successful at identifying high-risk individuals,3,4 many 
patients are still misdiagnosed. Patients diagnosed with 
non-cardiac chest pain account for a third of patients who 
subsequently die from cardiovascular disease or have an 
acute coronary syndrome during 5 years of follow-up.4 
Improved diagnostic accuracy and risk stratifi cation is 
needed, especially in younger patients.5
CT coronary angiography (CTCA) has a sensitivity of 
89% and specifi city of 96% for the detection of coronary 
heart disease.6 However, concerns have been raised about 
its generalisability in patients with cardiac disease, with the 
potential for poor image quality in those with obesity, 
coronary calcifi cation, or arrhythmia, and the high levels of 
radiation exposure (about 15 mSv).6,7 However, the evolution 
of scanning technology has led to improved spatial and 
temporal resolution with lower radiation doses that should 
translate into a more eff ective and safer imaging strategy.
Most clinical trials have focused on assessing the 
accuracy and comparability of CTCA for the identifi cation 
of coronary heart disease.8–10 In one study,11 investigators 
assessed the eff ect of CTCA on the management of low-
risk patients presenting to the emergency department 
with acute chest pain. Data from the study suggested 
improved decision making but an increase in further 
downstream testing and health-care costs without any 
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eff ect on cardiovasular outcomes.11 By contrast, the 
benefi t of implementation of CTCA for patients 
presenting to the cardiology clinic with stable chest pain 
has not been systematically assessed.7,12 We aimed to 
investigate the eff ect of CTCA on the diagnosis, 
management, and outcome of patients referred to the 
cardiology clinic with suspected angina due to coronary 
heart disease.
Methods
Study design
In this open-label, parallel-group, randomised controlled 
trial, we recruited patients from 12 cardiology chest pain 
clinics across Scotland. The study design is described in 
detail elsewhere.13 The study was done with the approval 
of the research ethics committee.
Participants
Patients aged 18–75 years and referred by a primary-care 
physician to a dedicated cardiology chest pain clinic with 
stable suspected angina due to coronary heart disease 
were eligible for inclusion. Patients with acute chest pain 
are not seen in such clinics but are referred directly to the 
emergency department. Exclusion criteria were inability 
to undergo CT scanning, renal failure (serum creatinine 
>250 μmol/L or estimated glomerular fi ltration rate 
<30 mL/min), previous recruitment to the trial, major 
allergy to iodinated contrast media, inability to give 
informed consent, known pregnancy, and acute coronary 
syndrome within 3 months.
All patients underwent routine clinic assessment 
including, if deemed appropriate, symptom-limited 
exercise electrocardiography with the standard Bruce 
protocol. Symptoms (typical, atypical, or non-anginal chest 
pain according to the National Institute for Health and 
Care Excellence [NICE] defi nition12), diagnosis, investi-
gations, and treatment strategy were documented at the 
end of the clinic attendance, before randomisation. This 
included categorising (no, unlikely, probable, or yes) the 
likelihood of the diagnosis of coronary heart disease and 
angina due to coronary heart disease and documentation 
of the need for additional stress imaging, such as stress 
echocardiography, and radionuclide or magnetic resonance 
myocardial perfusion imaging, and invasive coronary 
angiography. Patients gave written informed consent.
Randomisation and masking
After recruitment, patients were randomly assigned (1:1) 
to standard care plus coronary calcium score and CTCA, 
or to standard care alone, by use of a web-based 
randomisation service to ensure allocation concealment. 
Randomisation used minimisation to ensure balance for 
age, sex, BMI, diabetes, history of coronary heart disease, 
atrial fi brillation, and baseline diagnosis of angina due to 
coronary heart disease.
Procedures
Cardiovascular risk was calculated with the ASSIGN 
score, a validated Scottish cardiovascular risk score that 
also incorporates social deprivation and family history of 
For the ASSIGN score see http://
assign-score.com/
 Research in context
Evidence before this study
Between 2007 and 2010, we searched PubMed for reports 
published in English with the search terms “computed 
tomography”, “coronary angiography”, “angina pectoris”, and 
“coronary heart disease”. We identifi ed a high-quality health 
technology assessment comprehensive systematic review that 
assessed the role of 64-multidetector CT coronary angiography 
(CTCA). In keeping with previous analyses from the European 
Society of Cardiology, the review confi rmed the diagnostic 
utility of CTCA in the identifi cation of coronary heart disease. 
However, this systemic review highlighted several areas that 
need further research and in particular highlighted the need to 
assess the usefulness of multidetector CTCA in patients with 
suspected coronary heart disease. Shortly afterwards, the 
National Institute for Health and Care Excellence (NICE) 
outlined recommendations for the assessment and 
investigation of recent onset chest pain or discomfort of 
suspected cardiac origin. These guidelines specifi cally called for 
research into the clinical and cost-eff ectiveness of CTCA in the 
diagnosis of angina pectoris due to coronary heart disease.
One study has assessed the eff ect of CTCA on the management 
of low-risk patients presenting to the emergency department 
with acute chest pain. The data suggested improved decision 
making but an increase in further downstream testing and 
health-care costs without any eff ect on cardiovasular outcomes. 
By contrast, the benefi t of implementing CTCA for patients 
presenting to the cardiology clinic with stable chest pain has 
not been systematically assessed.
Added value of this study
We provide new information about the eff ect of CTCA on the 
diagnosis, management, and outcome of patients referred to 
the cardiology clinic with suspected angina due to coronary 
heart disease.
Implications of all the available evidence
The addition of CTCA to standard clinical care markedly clarifi es 
the diagnosis of angina due to coronary heart disease. This 
method reduces the need for further stress testing, increases the 
use of invasive coronary angiography, and results in more 
focused treatment regimes that are associated with an apparent 
reduction in fatal and non-fatal myocardial infarction. Further 
longer term follow-up and health economic assessment are 
needed to establish the clinical and cost-eff ectiveness of CTCA 
before adoption into routine clinical practice.
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cardiovascular disease.14 CT scans were done with 
64 detector row scanner (Brilliance 64, Philips Medical 
Systems, Netherlands, and Biograph mCT, Siemens, 
Germany) and 320 detector row scanner (Aquilion ONE, 
Toshiba Medical Systems, Japan) at three imaging sites. 
All CT coronary angiograms were assessed by at least two 
accredited assessors (a cardiologist and a radiologist) and 
the fi rst 40 scans from each imaging site underwent 
independent central validation to ensure consistency of 
approach. Obstructive coronary artery disease was 
defi ned as a luminal stenosis more than 70% in one or 
more major epicardial vessel or more than 50% in the 
left main stem.12 Luminal cross-sectional area stenoses 
were classifi ed as normal (<10%), mild non-obstructive 
(10–49%), moderate non-obstructive (50–70%), or 
obstructive (>70%). Assessors reported the presence of 
coronary heart disease with excellent intra-observer 
agreement of 95% and inter-observer agreement of 91%.
Outcomes
The primary endpoint of the study was the proportion of 
patients diagnosed with angina pectoris secondary to 
coronary heart disease at 6 weeks. Long-term outcomes 
were death, myocardial infarction, coronary re-
vascularisation procedures, admittance to hospital for 
chest pain episodes, cerebrovascular disease, and 
peripheral vascular disease, and were identifi ed with data 
from the Information and Statistics Division of the 
National Health Service (NHS) Scotland and, when 
appropriate, confi rmed by review of patient health 
records. Categorisation for analysis was done masked to 
randomised allocation.
At 6 weeks, the attendant clinician was asked to review 
their patients’ diagnosis and management plan in view of 
all available information including the CTCA report 
(standard care plus CTCA) or the ASSIGN score (standard 
care alone). The attending clinician documented all 
alterations in the diagnosis, investigations (eg, further 
stress testing or invasive coronary angiography), or 
treatments (eg, preventive and antianginal treatments). 
Like at baseline, patients’ anginal symptoms were assessed 
by a self-administered Seattle Angina Questionnaire,15 with 
telephone follow-up for non-responders after two mailings 
two weeks apart.
For safety outcomes, radiation doses were recorded as 
the dose-length product and the eff ective radiation dose 
calculated (0·014 mSv/mGy·cm conversion factor). We 
noted adverse reactions to the scanning procedure—eg, 
contrast reaction, renal impairment or vasovagal 
response. We recorded the presence of incidental 
fi ndings and whether they could provide an alternative 
diagnosis for the presenting chest pain.
Statistical analysis
For 80% power at a two-sided p value of 0·05, we aimed 
to recruit 2069 patients per group to detect an absolute 
change of 4% in the diagnosis of angina.
The diagnoses of coronary heart disease, and angina 
due to coronary heart disease (primary endpoint) were 
assessed for certainty (yes/no vs unlikely/probable in the 
primary analysis) and frequency (yes/probable vs 
9849 patients referred for assessment of suspected 
 angina due to coronary heart disease
8767 eligible patients for SCOT-HEART trial
1082 ineligible patients
4146 eligible recruited patients for SCOT-HEART trial
4146 randomly assigned
4621 eligible non-recruited patients
 2613 patient preference
 992 not approached
 547 clinician choice
 332 other
 137 missing
1778 CTCA
 Reason for non-compliance
  6 ill-health/death
 245 patient default
  10 technical
  34 other
3 CTCA
2073 standard of care 2073 standard of care plus CTCA
2073 data for primary endpoint 2073 data for primary endpoint
Figure 1: Trial Profi le
CTCA=CT coronary angiography.
All participants 
(n=4146)
Standard care and 
CTCA (n=2073)
Standard care 
(n=2073)
Men 2325 (56%) 1162 (56%) 1163 (56%)
Age (years) 57·1±9·7 57·1±9·7 57·0±9·7
BMI (kg/m2) 29·7±5·9 29·7±5·8 29·8±6·0
Atrial fi brillation 84 (2%) 42 (2%) 42 (2%)
Previous CHD 372 (9%) 186 (9%) 186 (9%)
Previous CVD 139 (3%) 91 (4%) 48 (2%)
Previous PVD 53 (1%) 36 (2%) 17 (1%)
Smoking habit* 2185 (53%) 1095 (53%) 1090 (53%)
Hypertension 1395 (34%) 712 (34%) 683 (33%)
Diabetes 444 (11%) 223 (11%) 221 (11%)
Hypercholesterolaemia 2176 (53%) 1099 (53%) 1077 (52%)
Family history 1716 (41%) 887 (43%) 829 (40%)
(Table 1 continues on next page)
Articles
4 www.thelancet.com   Published online March 15, 2015   http://dx.doi.org/10.1016/S0140-6736(15)60291-4
unlikely/no). These categories were analysed with 
logistic regression and adjusted for centre and 
minimisation variables excluding the baseline diagnosis. 
Odds ratios were converted into relative risks for 
presentation.16 Secondary binary outcomes were analysed 
in a similar way. All analyses were intention to treat, and 
patients were analysed in the group they were allocated 
to, irrespective of compliance with scanning. Missing 
data were removed from analyses, except for survival 
endpoints when they were censored at the time that they 
were lost from the study. Clinical outcomes from routine 
data were analysed with Cox regression, adjusted as 
before, and Kaplan-Meier plots were constructed. Data 
are presented as mean±standard deviation, median 
(IQR), and relative risk or hazard ratio (95% CI) as 
appropriate. Statistical signifi cance was taken as a two-
sided p value of less than 0·05.
Role of the funding source
The funder had no role in the trial conduct including 
data collection, analysis, interpretation, writing of the 
manuscript, and the decision to submit. The data were 
analysed by Edinburgh Clinical Trials Unit. The Trial 
Steering Committee and the Chief Investigator were 
responsible for the decision to submit the manuscript. 
Toshiba, Siemens, and Philips had no role in the trial 
conduct.
Results
Between Nov 18, 2010, and Sept 24, 2014, we randomly 
assigned 4146 (42%) of 9849 patients who had been 
referred for assessment of suspected angina due to 
coronary heart disease at 12 cardiology centres across 
Scotland (fi gure 1). Table 1 shows baseline characteristics. 
Few participants had a history of cardiovascular disease, 
but there was a high prevalence of cardiovascular risk 
factors and preventive treatments associated with a high 
10-year risk of coronary heart disease events. At the initial 
clinic assessment, most participants had anginal chest 
pain with limiting symptoms and most underwent 
exercise electrocardiography stress testing (table 1). At 
baseline, the attending clinician established that half the 
participants had coronary heart disease and a third had 
angina due to coronary heart disease.
After clinic consultation, 2073 participants were 
randomly assigned to CTCA, of whom 295 defaulted or 
did not complete the scan (appendix). Participants who 
defaulted were less likely to have typical anginal chest 
pain (58 [23%] vs 686 [39%]; p<0·0001) or have a diagnosis 
of angina due to coronary heart disease (50 [20%] vs 692 
[38%]; p<0·0001).
Of those 1778 participants who underwent CTCA, 31 (2%) 
had an adverse event related to the CTCA (13 contrast 
reactions, seven contrast extravasations, four vasovagal 
reactions, four headaches, and three other reactions). All 
adverse events were mild and self-limiting with no cases 
of anaphylaxis or renal failure. The median radiation 
dose was 4·1 (IQR 3·0–5·6) mSv, (dose-length product 
291 [216–397] mGy·cm); more than a third (37%) of the 
dose was attributable to the measurement of the coronary 
artery calcium score. CTCAs were mainly done with the 
320 detector row scanner (n=1343) and overall diagnostic 
quality was achieved in 95%. Most participants (63%) 
had evidence of coronary heart disease with a quarter 
having obstructive disease (table 2). In the opinion of the 
clinicians reporting the CTCA, this fi nding markedly 
All participants 
(n=4146)
Standard care and 
CTCA (n=2073)
Standard care 
(n=2073)
(Continued from previous page)
Serum cholesterol (mmol/L)
Total 5·41±1·20 5·41±1·23 5·41±1·17
HDL 1·35±0·43 1·35±0·42 1·35±0·43
Antiplatelet agent 1993 (48%) 1009 (49%) 984 (48%)
Statin 1786 (43%) 902 (44%) 884 (43%)
β-blockade 1357 (33%) 685 (33%) 672 (32%)
ACE inhibitor or ARB 685 (17%) 341 (16%) 344 (17%)
Calcium channel blocker 377 (9%) 183 (9%) 194 (9%)
Nitrates 1160 (28%) 570 (28%) 590 (29%)
Other antianginal treatment 191 (5%) 95 (5%) 96 (5%)
Anginal symptoms†
Typical 1462 (35%) 737 (36%) 725 (35%)
Atypical 988 (24%) 502 (24%) 486 (23%)
Non-anginal 1692 (41%) 833 (40%) 859 (41%)
Seattle Angina Questionnaire
Physical limitation 74±22 73±22 74±22
Angina stability 44±28 44±28 44±28
Angina frequency 68±22 68±22 68±22
Treatment satisfaction 92±12 92±12 92±13
Quality of life 55±21 55±21 55±22
Electrocardiogram
Normal 3492 (84%) 1757 (85%) 1735 (84%)
Abnormal 608 (15%) 292 (14%) 316 (15%)
Stress electrocardiograph
Performed 3517 (85%) 1764 (85%) 1753 (85%)
Normal 2188 (62%) 1103 (63%) 1085 (62%)
Inconclusive 566 (16%) 284 (16%) 282 (16%)
Abnormal‡ 529 (15%) 264 (15%) 265 (15%)
Further investigation
Stress imaging 1315 (32%) 633 (31%) 682 (33%)
Radionuclide 389 (9%) 176 (9%) 213 (10%)
Other 30 (1%) 16 (1%) 14 (1%)
Invasive coronary angiography 515 (12%) 255 (12%) 260 (13%)
Baseline diagnosis
CHD 1938 (47%) 982 (47%) 956 (46%)
Angina due to CHD 1485 (36%) 742 (36%) 743 (36%)
Predicted 10-year CHD risk§ 17±12% 18±11% 17±12%
Data are n (%) or mean ± SD. CTCA=CT coronary angiography. CHD=coronary heart disease. CVD=cerebrovascular 
disease. PVD=peripheral vascular disease. HDL=high density lipoprotein. ACE=angiotensin-converting enzyme. 
ARB=angiotensin receptor blocker. *Current and ex-smokers. †National Institute for health and Care Excellence criteria. 
‡Evidence of myocardial ischaemia. §ASSIGN score. 
Table 1: Baseline participant characteristics and clinic assessment
See Online for appendix
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increased the certainty (relative risk [RR] 3·76, 95% CI 
3·61–3·89; p<0·0001) but reduced the frequency (0·78, 
0·70–0·86; p<0·0001), of the diagnosis of angina due to 
coronary heart disease. We noted several incidental 
fi ndings that were clinically important or identifi ed non-
coronary causes of chest pain (table 2).
The attending clinician reported that, compared with 
standard care, CTCA increased the certainty (RR 2·56, 
95% CI 2·33–2·79; p<0·0001) and frequency (1·09, 
1·02–1·17; p=0·0172) of the diagnosis of coronary heart 
disease at 6 weeks (table 3). For the primary endpoint, this 
translated into an increased certainty (1·79, 1·62–1·96; 
p<0·0001) but no eff ect on frequency (0·93, 0·85–1·02; 
p=0·1289) of the diagnosis of angina due to coronary heart 
disease. Overall, the 6-week diagnosis of coronary heart 
disease changed in 27% of participants assigned CTCA 
compared with 1% assigned to standard care and the 
6-week diagnosis of angina due to coronary heart disease 
in 23% of participants assigned CTCA compared with 1% 
assigned to standard care (p<0·001 for both).
Changes in the diagnosis were associated with changes 
in planned investigations (15% vs 1% respectively; 
p<0·0001; table 4). Specifi cally, the use of CTCA was 
associated with the cancellation of 121 functional stress 
tests and 29 invasive coronary angiograms. Conversely, 
CTCA was associated with 94 further invasive coronary 
angiograms (table 4). These changes were mainly the 
result of the exclusion or identifi cation of obstructive 
coronary heart disease (appendix).
The changes in diagnoses and investigations were 
associated with changes in the subsequent 
recommendations for preventive (18% vs 4% respectively; 
N (%)
Coronary calcium score 1159 (65%)
Low (<100 AU) 303 (17%)
Medium (100–400 AU) 315 (18%)
High (>400AU)
CTCA
Normal 654 (37%)
Non-obstructive CHD 672 (38%)
Mild (<50%) 372 (21%)
Moderate (50–70%) 300 (17%)
Obstructive CHD 452 (25%)
One vessel 207 (12%)
Two vessels 128 (7%)
Three vessels 117 (7%)
Other cardiac fi ndings 501 (28%)
Aortic valve calcifi cation 146 (8%)
Mitral valve calcifi cation 29 (2%)
Dilated left ventricle 38 (2%)
Dilated right ventricle 12 (1%)
Dilated left atrium 80 (5%)
Dilated right atrium 11 (1%)
Left ventricular wall thinning 33 (2%)
Left ventricular hypertrophy 70 (4%)
Hypertrophic obstructive 
cardiomyopathy
4 (0·2%)
Other 232 (13%)
Non-cardiac fi ndings 677 (38%)
Parenchymal lung disease 281 (16%)
Pulmonary mass or nodule 188 (11%)
Emphysema 154 (9%)
Hiatus hernia 135 (8%)
Liver pathology 40 (2%)
Lymphadenopathy 13 (1%)
Pulmonary embolism 5 (0·3%)
Data are n (%). AU=Agatston Units. CTCA=CT coronary angiography. 
CHD=coronary heart disease. 
Table 2: Findings of CTCA (n=1778)
6-week diagnosis
Yes Probable Unlikely No Total
Diagnosis of coronary heart disease
Standard care and CTCA
Baseline diagnosis
Yes 197 (10%)* 2 (0%) 4 (0%) 7 (0%) 210 (10%)
Probable 148 (7%) 490 (24%)* 26 (1%) 107 (5%) 771 (37%)
Unlikely 124 (6%) 48 (2%) 698 (34%)* 80 (4%) 950 (46%)
No 7 (0%) 4 (0%) 1 (0%) 126 (6%)* 138 (7%)
Total 476 (23%) 544 (26%) 729 (35%) 320 (15%) 2069 (100%)
Standard care
Baseline diagnosis
Yes 220 (11%)* 1 (0%) 0 (0%) 1 (0%) 222 (11%)
Probable 0 (0%) 721 (35%)* 6 (0%) 7 (0%) 734 (35%)
Unlikely 1 (0%) 6 (0%) 975 (47%)* 0 (0%) 982 (47%)
No 0 (0%) 0 (0%) 0 (0%) 132 (6%)* 132 (6%)
Total 221 (11%) 728 (35%) 981 (47%) 140 (7%) 2070 (100%)
Diagnosis of angina due to coronary heart disease
Standard care and CTCA
Baseline diagnosis
Yes 126 (6%)* 0 (0%) 6 (0%) 8 (0%) 140 (7%)
Probable 69 (3%) 402 (19%)* 52 (3%) 77 (4%) 600 (29%)
Unlikely 33 (2%) 55 (3%) 822 (40%)* 151 (7%) 1061 (51%)
No 3 (0%) 8 (0%) 19 (1%) 237 (11%)* 267 (13%)
Total 231 (11%) 465 (22%) 899 (43%) 473 (23%) 2068 (100%)
Standard care
Baseline diagnosis
Yes 139 (7%)* 1 (0%) 1 (0%) 0 (0%) 141 (7%)
Probable 2 (0%) 588 (28%)* 5 (0%) 7 (0%) 602 (29%)
Unlikely 2 (0%) 4 (0%) 1055 (51%)* 0 (0%) 1061 (51%)
No 0 (0%) 0 (0%) 1 (0%) 265 (13%)* 266 (13%)
Total 143 (7%) 593 (29%) 1062 (51%) 272 (13%) 2070 (100%)
Data are n (%). Clinicians were asked to diagnose both coronary heart disease, and angina due to coronary heart 
disease, in view of all available information. They were asked to categorise this according to the level of confi dence in 
their diagnosis (yes, probable, unlikely, or no) both at baseline and at 6 weeks after the result of the CTCA (standard 
care and CTCA) and ASSIGN score (standard care). Certainty of the diagnosis was assessed by comparing yes/no with 
probable/unlikely. Frequency of the diagnosis was compared between yes/probable and unlikely/no. CTCA=CT coronary 
angiography. *Complete agreement at baseline and 6 weeks. 
 Table 3: Baseline and 6-week diagnoses of coronary heart disease and angina due to coronary heart disease
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p<0·0001) and antianginal (9% vs 1% respectively; 
p<0·0001) treatments (table 4). Although the use of 
antianginal treatment was reduced, CTCA was not 
associated with an increase in the proportion of coronary 
revascularisation (11·2 vs 9·7%; p=0·0611; table 5, 
fi gure 2, and appendix).
Results of the Seattle Angina Questionnaire showed 
that treatment satisfaction was excellent at the baseline 
clinic attendance (92/100). Compared with baseline, 
angina stability and frequency markedly improved at 
6 weeks in patients undergoing CTCA (n=640, 44±28 to 
62±24 at baseline; p<0·001; and n=655, 68±22 to 79±23; 
p<0·0001, respectively) and in those assigned standard 
care (n=651, 44±28 to 61±24; p<0·0001 at baseline; and 
n=653, 68±22 to 80±23; p<0·0001, respectively). We 
noted no diff erences in the improvements in angina 
stability and frequency between the randomised groups 
(between group diff erence, 1·02±0·84 [p=0·2234] and 
–0·87±0·70 p=0·2147]). Furthermore, we recorded no 
diff erences in subsequent numbers of admittance to 
hospital for chest pain (table 5 and appendix).
Patients were followed up for a median of 1·7 (range 
0·1–4·1) years. CTCA was associated with 38% reduction 
in coronary heart disease death and non-fatal myocardial 
infarction (fi gure 2) although, for the prespecifi ed 
analysis, this fell just short of statistical signifi cance 
(adjusted HR 0·62, 95% CI 0·38–1·01; p=0·0527).
Discussion
In this large multicentre randomised clinical trial, the 
addition of CTCA to standard clinical care clarifi ed the 
diagnosis of angina due to coronary heart disease. This 
reduced the need for further stress testing, increased the 
use of invasive coronary angiography, and changed 
treatment regimes that might be associated with a 
reduction in fatal and non-fatal myocardial infarction.
This trial has fi ve major strengths. First, we included a 
broad and large population of patients who were 
representative of those referred to the cardiology clinic 
for assessment of suspected angina due to coronary heart 
disease. Second, we specifi cally included patients who 
had been excluded from previous studies of CTCA such 
as those with obesity, high calcium scores, and atrial 
fi brillation. Despite their inclusion, we obtained 
diagnostic information in 99% of patients. Third, we 
allowed unrestricted use of further stress imaging in 
keeping with clinician choice and routine practice 
because we wanted to explore the eff ect of the addition of 
CTCA as opposed to doing a head-to-head comparison 
with other diagnostic approaches. Fourth, we focused on 
the eff ect of CTCA on patient-centred and clinician-
centred outcomes rather than comparing diagnostic 
accuracy between imaging modalities or anatomic versus 
functional testing. Finally, we assessed the eff ect of this 
intervention on both short-term and long-term outcomes 
to defi ne the impact of this additional imaging 
intervention to routine clinical practice.
All participants 
(n=4146)
Standard care and 
CTCA (n=2073)
Standard care 
(n=2073)
HR (95% Wald 
confi dence limits)
p value*
CHD death† and myocardial infarction 68 (1·6%) 26 (1·3%) 42 (2·0%) 0·616 (0·378–1·006) 0·0527
CHD death†, myocardial infarction , and stroke 79 (1·9%) 31 (1·5%) 48 (2·3%) 0·644 (0·410–1·012) 0·0561
Non-fatal myocardial infarction 57 (1·4%) 22 (1·1%) 35 (1·7%) 0·627 (0·367–1·069) 0·0862
Non-fatal stroke 12 (0·3%) 5 (0·1%) 7 (0·2%) 0·727 (0·228–2·315) 0·5900
All-cause death 37 (0·9%) 17 (0·8%) 20 (1·0%) 0·860 (0·450–1·642) 0·6468
Cardiovascular death† 11 (0·3%) 4 (0·2%) 7 (0·3%) 0·574 (0·167–1·971) 0·3776
Non-cardiovascular death 26 (0·6%) 13 (0·6%) 13 (0·6%) 1·006 (0·466–2·172) 0·9879
Coronary revascularisation‡ 434 (10·7%) 233 (11·2%) 201 (9·7%) 1·198 (0·992–1·448) 0·0611
Percutaneous coronary intervention 344 (8·3%) 184 (8·9%) 160 (7·7%) 1·190 (0·963–1·472) 0·1075
Coronary artery bypass graft surgery 99 (2·4%) 54 (2·6%) 45 (2·2%) 1·218 (0·819–1·812) 0·3304
Hospitalisation for chest pain§ 511 (12·3%) 247 (11·9%) 264 (12·7%) 0·928 (0·780–1·104) 0·3993
Cardiac chest pain 145 (3·5%) 76 (3·7%) 69 (3·3%) 1·115 (0·805–1·545) 0·5130
Non-cardiac chest pain 391 (9·4%) 183 (8·8%) 208 (10·0%) 0·864 (0·708–1·054) 0·1498
CTCA=CT coronary angiography. HR=hazad ratio. CHD=coronary heart disease.*Cox regression. †Cause of death was certifi ed as myocardial infarction in all cases. ‡Nine 
patients had percutaneous coronary intervention followed by coronary artery bypass surgery. §Some patients had admissions for both cardiac and non-cardiac chest pain. 
Table 5: Clinical outcomes
Standard care and CTCA Standard care
Cancellation New Cancellation New
Investigations
Stress imaging 121 5 0 6
Invasive coronary angiography 29 94 1 8
Total 150 99 1 14
Medical treatments
Preventive treatment 77 293 8 84
Antianginal treatment 112 82 6 11
Total 189 375 14 95
CTCA=CT coronary angiography. 
 Table 4: Changes in investigations and treatments at 6 weeks
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In our study, 36% of patients were diagnosed with angina 
due to coronary heart disease in the clinic. We noted that 
although the certainty and frequency of the diagnosis of 
coronary heart disease increased, the overall diagnostic rate 
of angina due to coronary heart disease did not change or 
seemed to fall with the introduction of CTCA. This fi nding 
suggests clinicians tend to overdiagnose angina due to 
coronary heart disease, probably for fear of undertreatment. 
However, CTCA did diagnose many patients with angina 
due to coronary heart disease who had been misclassifi ed 
in the clinic. Overall reclassifi cation happened in one in 
four patients and this is clearly important for the 
subsequent investigation and treatment of these patients.
In view of its strong negative predictive value, the 
cancellation of invasive coronary angiography with the 
use of CTCA would be anticipated. However, CTCA 
caused a modest net increase in use of invasive coronary 
angiography. These extra invasive coronary angiograms 
showed obstructive coronary heart disease in most 
patients, including those with severe triple vessel disease. 
Indeed CTCA was associated with an apparent increase 
in coronary revascularisation, although this fell just short 
of statistical signifi cance. 
CTCA undoubtedly increased the identifi cation of both 
obstructive and non-obstructive coronary atherosclerosis. 
This fi nding led to changes in preventive treatments 
despite a high prevalence of such treatments at baseline. 
In keeping with the changes in diagnoses, overall 
preventive treatment was increased and antianginal 
treatment was decreased. One in four patients had 
changes to their treatment.
Treatment satisfaction at the clinic was high and 
symptoms improved markedly by 6 weeks, but we 
recorded no short-term diff erences in the frequency and 
severity of symptoms between the allocated groups. In 
view of the marked improvement in symptoms with 
standard care and the reduction of antianginal treatment 
with CTCA, it is perhaps not surprising that there was no 
eff ect on 6-week symptom severity. It will be interesting 
to see whether diff erences can be seen with longer 
follow-up at 6 months when the potential eff ect of 
coronary revascularisation will have had chance to take 
eff ect. However, CTCA did not seem to prevent 
subsequent admittance of patients to hospital with chest 
pain, suggesting admission with chest pain is not 
dependent on whether there is uncertainty regarding the 
presence of coronary heart disease.
We had anticipated that a signifi cant early change in 
overall clinical outcome would be unlikely because most 
patients had normal coronary arteries or mild coronary 
heart disease. Indeed, the overall absolute event rate 
during a median of 1·7 years of follow-up was low at 2%. 
However, we recorded a 38% reduction in myocardial 
Figure 2: Kaplan-Meier curves for CHD death and myocardial infarction (A), 
CHD death, myocardial infarction, and stroke (B), and coronary 
revascularisation (C) in patients assigned to CTCA (blue) and standard 
care (red)
Each cross-hair shows when a participant is censored from further follow-up. 
The number at risk for each yearly interval is given for each randomised 
allocation group. CHD=coronary heart disease. CTCA=CT coronary angiography. 
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infarction in those randomly assigned to CTCA. We 
acknowledges that the absolute number of events was 
modest, the fi nding was borderline signifi cant, and 
further long-term follow-up is needed. However, we 
believe that this fi nding is in keeping with the 
improvements in the management and treatment 
consequent on the clearer diagnosis of coronary heart 
disease, especially because patients with recent onset 
angina have an increased risk of early events.1,4 Indeed, we 
recorded a higher event rate in the fi rst few months 
following clinic consultation (fi gure 2). Although coronary 
revascularisation is not associated with improved 
outcomes in patients with chronic stable coronary heart 
disease,17 it is associated with improved outcomes in those 
with acute coronary syndromes.18 Therefore, we suggest 
that patients with recent onset angina due to coronary 
heart disease are an intermediate risk group, and that this 
plausibly accounts for the trend towards a reduction in 
coronary events from the combination of changes in 
medical treatment and coronary revascularisation.
Our trial has several important limitations. First, this 
was an open trial and attending clinicians might favour 
either CTCA or functional tests, which could have 
aff ected their decision making. Irrespective of clinician 
bias, it undoubtedly changed clinician behaviour and the 
apparent trends to improved clinical outcomes provide 
inferential evidence that this diagnostic test was 
benefi cial for the patient. Second, the Kaplan-Meier 
curves for clinical outcomes seem to suggest that 
alterations in patient management consequent on the 
CTCA might have taken more than 6 weeks to be 
eff ectively implemented in some patients. Therefore, we 
cannot confi dently exclude an eff ect on anginal 
symptoms and further long-term follow-up is planned. 
Third, the cost-eff ectiveness of CTCA and the 
downstream health-care resource utilisation do need to 
be studied. We intend to undertake a health economic 
assessment of CTCA in this clinical setting and explore 
whether there are specifi c patient subgroups that would 
potentially benefi t from this intervention. Finally, we 
excluded patients older than 75 years. We were concerned 
that most of these patients would have evidence of 
coronary heart disease, and the application of CTCA to 
this population would be less discriminatory. We were 
also concerned preventive interventions that aff ect 
outcomes have a weaker eff ect in elderly people.19 This 
would potentially hinder our ability to assess whether 
CTCA had an eff ect on long-term outcomes. Coronary 
calcifi cation would also be higher and consequently 
CTCA might not be as useful in this age group.
In conclusion, in patients with suspected angina due to 
coronary heart disease, CTCA clarifi es the diagnosis and 
leads to major alterations in investigations and 
treatments. There is a suggestion that this fi nding is 
associated with apparent improvements in fatal and non-
fatal coronary events, but this needs to be confi rmed by 
further long-term follow-up.
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